Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endovascular Devices Headline International Stroke Conference

This article was originally published in The Gray Sheet

Executive Summary

The American Heart Association-sponsored conference in Nashville featured late-breaking presentations of data from several major neurointerventional device trials as well as meta-analysis and pooled results confirming the benefits of endovascular intervention in several difficult-to-treat populations of stroke patients.

You may also be interested in...

Companies Support Telehealth Reforms – But Seek Demo Projects First

Responding to a chronic care reform effort by the Senate Finance Committee, AdvaMed, device firms and several medical groups asked for demo projects and waivers to appropriately expand the use of telehealth services.

PODCAST: A New Era In Stroke Care – An Interview With Medtronic's Brett Wall

Positive data from five clinical trials and new treatment guidelines for mechanical thrombectomy devices have ushered in a new era in stroke care. In this first in a new series of podcasts, Medtech Insight spoke at the recent SNIS meeting with Brett Wall, vice president and president of the Neurovascular group at Medtronic, to find out what impact the trials and guidelines are having on stroke care, the market for mechanical thrombectomy devices, demand for Solitaire FR and the company's plans for innovation.

FDA Plans Acute Stroke Device Workshop; Guidance Could Follow

The October workshop will focus discussion on clinical study trial designs, patient populations, and patient selection methods, as well as study endpoints for devices targeting ischemic stroke, FDA says.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts